Bio-Rad Launches Celselect Slides 2.0 to Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research

June 27, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Celselect Slides 2.0 to enhance rare cell and circulating tumor cell (CTC) capture. Compatible with Bio-Rad’s Genesis Cell Isolation System, the latest version of Celselect Slides enables the processing of greater volumes of liquid biopsy samples and offers the ability to capture and recover a greater number of CTCs for enumeration or use in downstream applications.

The Genesis Cell Isolation System provides researchers with unbiased size-based microfluidic cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples such as blood in one benchtop solution. The latest version of Celselect Slides allows researchers to load 2.5x more sample per slide compared to Celselect Slides 1.0, increasing the sample volume from 4 ml to 10 ml. The number of microchambers in which CTCs are captured has also increased, from 56,400 in the version 1.0 slides to 140,800 in the version 2.0 slides. The Genesis System’s two-bay design accepts two Celselect Slides that can be run independently, now permitting a total volume of 20 ml of sample to be processed at one time. Bio-Rad’s new slide design is also compatible with full standard blood tube runs (~8 ml), allowing seamless integration into researchers’ existing workflows.

The increased volume of liquid biopsy sample accepted by the Genesis Cell Isolation System will allow researchers to process a larger amount of sample in a single run, improving the efficiency of CTC capture. This will increase the number of viable CTCs captured for immunofluorescence applications such as enumeration and identification of various CTC types, for downstream analyses such as next-generation sequencing or Droplet Digital™ PCR, or for sub-cultivation

“CTCs are rare — as low as only 1–10 can be found per milliliter of blood — however, CTC enumeration and analysis offers valuable insight into tumor heterogeneity and disease progression,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Building on the capabilities of Celselect Slides 1.0, we’re continuing to improve the efficiency of rare CTC enrichment, enumeration, and recovery to accelerate cancer research workflows. This launch reflects the expansion of our technological capabilities and our commitment to bringing novel solutions to researchers to improve our understanding of cancer and inform research programs.”

UltraSight Joins Butterfly Garden to Expand AI Real-Time Guidance Across Point of Care Ultrasound Devices

June 27, 2024

Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has joined Butterfly Garden, an artificial intelligence (AI) Marketplace launched by Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software.

UltraSight and Butterfly have partnered to increase patient access to cardiac care by enabling more healthcare professionals to perform cardiac ultrasound. Subject to regulatory approvals and authorizations, UltraSight aims to integrate and deploy its real-time AI guidance software on Butterfly’s imaging platform and build the software for use with Butterfly’s single-probe, whole-body handheld ultrasound system.

Cardiovascular disease (CVD) is the leading global cause of death, accounting for an estimated 18 million deaths yearly. Today patients face significant delays in receiving crucial cardiac testing due to a fragmented market full of system bottlenecks, in addition to a national shortage of expert sonographers.

UltraSight’s mission is to empower any medical professional, including novice users with no prior sonography experience, to confidently conduct echocardiographic examinations and capture diagnostic quality cardiac ultrasound images at the point of care. Achieving compatibility with the most prominent handheld ultrasound device companies in the market, such as Butterfly, facilitates the company’s goal of increasing access to cardiac care and reducing system bottlenecks for patients.

“Joining the Butterfly Garden marks an important moment in our mission to revolutionize cardiac care,” said Davidi Vortman, CEO of UltraSight. “By integrating our real-time AI guidance software with Butterfly’s cutting-edge ultrasound technology, we are poised to transform the landscape of cardiac imaging. This collaboration will empower healthcare professionals, regardless of their experience level, to perform accurate and timely cardiac ultrasound exams at the point of care. Together, we will break down existing barriers in cardiac care, ensuring that more patients receive the critical diagnostics they need, when and where they need it most.”

“We are thrilled to partner with UltraSight to bring their AI guidance software to Butterfly devices in an effort to mitigate the pressing issue of sonographer shortages, among other workforce challenges, impacting medical communities around the world,” said Darius Shahida, chief strategy officer of Butterfly Network. “UltraSight and Butterfly are jointly dedicated to making healthcare more efficient, effective and accessible through high-quality ultrasound that’s easy-to-use and globally available.”

In August 2023, Butterfly Network launched Butterfly Garden, allowing third-party developers access to its proprietary SDK and APIs to build new AI applications that work in conjunction with Butterfly’s imaging platform, bringing with it access to the largest point-of-care ultrasound customer base. UltraSight, with capabilities to provide more medical professionals with the ability to take high-quality diagnostic images of the heart, has the potential to close the gap between novice and skilled Butterfly ultrasound users, and is an ideal match for the program.

When paired with ultrasound devices, and following the appropriate regulatory clearance for each device, UltraSight’s underlying AI neural network can predict the position of the ultrasound probe relative to the heart based on the ultrasound video stream and guide the user on maneuvering the probe to capture diagnostic quality cardiac images.

UltraSight’s partnership with Butterfly follows a series of recent collaborations with other industry leaders such as Mayo Clinic and EchoNous. For more information about UltraSight, visit www.ultrasight.com. For more information about Butterfly, visit www.butterflynetwork.com.

Neuromod Partners with 14 New US Tinnitus Clinics to Expand Availability of FDA Approved Lenire

June 27, 2024

Neuromod Devices, the medical technology company that developed tinnitus treatment device, Lenire, has partnered with 14 new US clinics to address the growing demand for the first and only FDA Approved tinnitus treatment device.

Lenire^® is a groundbreaking bimodal neuromodulation device which has been proven to provide clinically significant relief from tinnitus in clinical trial and real-world settings.^1,2,3

Tinnitus, commonly known as “ringing in the ears”, is a complex brain signaling condition that causes people to perceive sound with no external source.

Lenire has become the most in-demand tinnitus treatment device in America since the device was awarded a De Novo FDA Approval Grant in 2023. Neuromod Devices, creators of Lenire, is operating a phased expansion to prioritize patient care excellence at scale.

This latest expansion will see the clinically proven tinnitus treatment device become available in new states such as Alabama, Oregon, and North Dakota, and more. As well as this, further clinics will open in states with significant demand such as California, Florida, Illinois, and Texas.

Founder of Alabama Hearing Associates, Dr. Susan Sheehy believes that evidence-based Lenire is a “fantastic opportunity” for her patients to get relief from tinnitus.

“Alabama Hearing Associates has worked with tinnitus patients for over twenty-four years. Our clinic firmly believes in offering evidence-based treatment options when managing a patient’s tinnitus journey. For that reason, we are excited to add FDA-approved Lenire to our list of tinnitus services. This is a fantastic new opportunity to help our patients return to the quality of life they had before tinnitus.” Dr. Susan Sheehy, Au.D., Founder of Alabama Hearing Associates.

Tinnitus, which is commonly known as ‘ringing in the ears’, is a complex neurological condition that causes a perception of sound when there is no external source. It is estimated that at least 25 million Americans⁶ are currently living with tinnitus. Tinnitus is also the most prevalent service-connected disability compensated for by The United States Veterans Administration (VA), with more than 2.9 million veterans compensated in 2023.⁴

Neuromod Devices aims to change this by working with leading tinnitus care experts in the United States of America and beyond. 144 audiologists in 87 clinics across America are now providing Lenire with further expansion planned through 2024.

“Neuromod’s mission is to create a new standard of care for tinnitus patients, and this goal is achievable only through collaboration with leading hearing and tinnitus care professionals. We are proud to expand Lenire’s accessibility by establishing partnerships with professionals who share Neuromod’s uncompromising patient-centric approach to tinnitus care.” said Eric Timm, Neuromod USA CEO and Neuromod Devices President of Global Commercial Operations.

Lenire’s demand is owed to being the first device of its kind to be awarded a De Novo Grant from the US FDA. Lenire’s landmark FDA Approval was awarded following the success of Lenire’s third large-scale clinical trial, TENT-A3.

Lenire’s De Novo submission demonstrated that 70.5% of patients with moderate or worse tinnitus who experienced no clinically meaningful improvement from six weeks of sound-only therapy reported clinically significant improvement in their tinnitus severity following six weeks of treatment with Lenire.^1,5 As well as this, the majority of participants who underwent six weeks of sound-only stimulation reported that a further six weeks of treatment with Lenire provided additional benefit for their tinnitus.^1,5

In addition to the majority of participants benefitting from bimodal neuromodulation, 82.4% were compliant to bimodal treatment and 88.6% responded that they would recommend Lenire as a tinnitus treatment¹.

Lenire’s positive efficacy, compliance and safety findings for TENT-A3 were highly consistent with the Real-World Evidence from 204 patients included in Lenire’s successful De Novo submission to the US FDA. Across TENT-A3 and the Real-World Evidence, Lenire proved to be inherently safe with zero device-related serious adverse events¹. These results build upon the success of two previous landmark clinical trials of Lenire that included more than 500 patients.^2,3

Lenire® is a bimodal neuromodulation device which works by delivering mild electrical pulses to the tongue, through an intra-oral component called the ‘Tonguetip®’, combined with auditory stimulation through headphones to drive long-term changes in the brain to treat tinnitus. This dual action stimulus is proven to provide effective relief from tinnitus.¹

Tinnitus patients can learn more about Lenire, tinnitus and where to find a clinic near their location by visiting www.lenire.com.

VenoStent Completes $20 Million Series A with $4 Million Investment from Norwest Venture Partners

June 27, 2024

VenoStent, Inc., a clinical-stage medical device company developing a novel therapeutic device for improving dialysis patient outcomes, announced today that it closed an additional $4 million from Norwest Venture Partners to round out its Series A financing at $20 million with Good Growth Capital and IAG Capital Partners co-leading the deal. In addition, the company was awarded a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant by the National Institutes of Health (NIH), which will help fund its multi-center, 200-patient, randomized controlled trial (RCT) in the US.

Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are joining the company as board observers. Dr. Scott and Dr. Akhirome bring deep medtech expertise from previous experience as a surgeon and physician scientist, respectively.

“2024 has been a momentous year for VenoStent so far. In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest,” said Tim Boire, Ph.D., VenoStent CEO and co-founder. “We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible. Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration. These recent milestones will propel our company forward to an exciting next phase.”

As a clinical-stage therapeutic medical device company, VenoStent has developed a bioabsorbable perivascular wrap, SelfWrap, that goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The bioabsorable wrap is intended to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis. SelfWrap uses the body’s own healing mechanisms to mimic the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis.

In May 2023, SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study, SAVE-FistulaS: The SelfWrap-Assisted ArterioVEnous Fistulas Study. The study is designed to show how SelfWrap can improve clinical outcomes for CKD patients requiring hemodialysis. Based on the compelling results from the company’s first-in-human clinical trial, the FDA granted SelfWrap a Breakthrough Device Designation in May 2022.

“Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60%, which significantly impacts patients’ survival rates and quality of life,” said Norwest’s Dr. Scott. “VenoStent’s groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients.”

“Norwest’s investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company’s board,” said VenoStent COO and Co-Founder, Geoffrey Lucks. “Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar.”

Exploring the Pros and Cons of the PillCam for Endoscopy

June 25, 2024

The field of gastroenterology has seen significant advancements in diagnostic tools over the years, with one of the most revolutionary being the PillCam. This small, swallowable capsule contains a camera that captures images of the digestive tract, offering a non-invasive alternative to traditional endoscopy when administered by expert gastroenterologists. While the PillCam, also known as capsule endoscopy, presents numerous advantages, it also has certain limitations. This article explores the pros and cons of the PillCam to help patients and healthcare providers make informed decisions.

What is the PillCam?

The PillCam is a capsule endoscopy device developed to visualize the small intestine, which is challenging to examine with conventional endoscopy and colonoscopy. The capsule, about the size of a large vitamin pill, is swallowed by the patient. As it travels through the digestive tract, it captures thousands of images transmitted to a recording device worn by the patient. A gastroenterologist later reviews these images to diagnose various conditions.

Pros of the PillCam

Non-Invasive and Painless

One of the most significant advantages of the PillCam is its non-invasive. Traditional endoscopy involves inserting a flexible tube with a camera down the throat or through the rectum, which can be uncomfortable and require sedation. The PillCam, on the other hand, is simply swallowed like a pill, making the procedure painless and eliminating the need for sedation or anesthesia.

Convenient and Time-Efficient

The PillCam procedure is straightforward and can be completed in a normal daily setting. Patients can go about their daily activities while the capsule travels through their digestive tract, unlike traditional endoscopy, which requires a hospital or clinical setting and recovery time post-procedure.

Access to Difficult-to-Reach Areas

The small intestine is difficult to examine with conventional endoscopy and colonoscopy. The PillCam provides a unique advantage by capturing detailed images of the entire small intestine, allowing for the diagnosis of conditions like Crohn’s disease, small bowel tumors, and obscure gastrointestinal bleeding.

Lower Risk of Complications

Since the PillCam is non-invasive, it carries a lower risk of complications than traditional endoscopic procedures. There is no perforation, bleeding, or infection risk associated with inserting instruments into the body.

Cons of the PillCam

Limited to Imaging Only

While the PillCam excels at capturing images, it does not allow therapeutic interventions. Intraditional endoscopy, physicians can take biopsies, remove polyps, and perform other treatments during the procedure. If an abnormality is detected with the PillCam, a follow-up traditional endoscopy may still be required to perform these interventions.

Incomplete Examination

In some cases, the PillCam might not completely examine the digestive tract. The capsule can sometimes get stuck, especially in patients with strictures or narrowing of the intestines, leading to incomplete imaging. Additionally, rapid transit of the capsule through certain sections of the intestine can result in missed areas.

Battery Life Limitations

The PillCam’s battery life is limited, typically around 8-12 hours. If the capsule does not pass through the entire digestive tract within this time frame, parts of the intestine might not be imaged. This is particularly a concern in patients with slow gastrointestinal motility.

Cost and Accessibility

Capsule endoscopy can be more expensive than traditional endoscopy due to the cost of the disposable capsules. Additionally, not all medical facilities can perform capsule endoscopy, which may limit accessibility for some patients.

Conclusion

The PillCam represents a significant advancement in gastroenterological diagnostics, offering a non-invasive, convenient, and effective method for visualizing the small intestine. Its ability to reach areas that are difficult to examine with traditional methods is particularly valuable.

However, it has limitations, including its inability to perform therapeutic interventions, potential for incomplete examinations, battery life constraints, and cost considerations. Patients and healthcare providers must weigh these pros and cons when choosing the best diagnostic approach. In cases where detailed imaging of the small intestine is required without immediate therapeutic intervention, the PillCam is an excellent option. However, traditional endoscopy may still be necessary for comprehensive diagnostic and therapeutic needs. As with any medical procedure, consulting with a healthcare professional to determine the most appropriate course of action based on individual patient needs is essential.

Laudio Expands Work With Children’s National Hospital to Include Nurse Educators

June 25, 2024

Laudio, an innovator in frontline leader solutions that drive efficiency and engagement for health systems, today announced an expansion of its engagement with Children’s National Hospital, the leading pediatric health system in the Washington, DC area. The expansion will bring nurse educators at Children’s National onto the Laudio platform, building on the hospital’s original implementation with nurse managers in 2021.

Tom Hills, EVP of Client Engagement at Laudio…

“Setting nurses up for success, supporting them effectively, and ultimately retaining them requires increasingly proactive, comprehensive strategies. We are excited to welcome nurse educators at Children’s National into the Laudio community.”

The Laudio platform centralizes frontline leaders’ core workflows, automates repetitive tasks, and fosters meaningful team engagement. Unique, AI-driven recommendations help leaders prioritize high-impact opportunities with their teams and take action efficiently. Children’s National first implemented the platform during the pandemic, seeking innovative ways to relieve mounting pressure on managers and prevent burnout more broadly. The hospital has continued to use the platform to support this critical role and is extending it to nurse educators for a more holistic approach.

Children’s National has also used the unique data available through Laudio Insights, Laudio’s research arm. Last year, Dr. King published “Using Real-Time Data to Mitigate Nurse Burnout” with Laudio Insights President, Tim Darling. The article, published in Nurse Leader, focused on leveraging technology to identify and intervene early on nurse burnout risk.

PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera

June 25, 2024

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®).

The Phase 2b EXCEED-ET trial (NCT05482971), which is evaluating the effectiveness and safety of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia (ET), has exceeded the enrollment goal of 64 patients to include 91 patients. EXCEED-ET is evaluating people diagnosed with ET who are either treatment naïve or have received previous ET treatment with hydroxyurea or anagrelide but require a treatment change due to intolerance or because the previous treatment is no longer effective.

This trial is being conducted in the United States and Canada and will use the accelerated dosing schedule (250, 350, 500 mcg). This accelerated dosing schedule has been previously assessed in Asian clinical trials.

The Phase 3b ECLIPSE-PV trial (NCT05481151), assessing the effectiveness and safety of two dosing regimens of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera (PV), has also exceeded the enrollment goal of 100 patients to include 111 patients. ECLIPSE-PV is evaluating two ropeginterferon alfa-2b-njft doses, including the accelerated dosing schedule (as described above) in comparison to the current recommended dosing regimen. The ECLIPSE-PV study is being performed in the United States and Canada.

“Myeloproliferative neoplasms, including ET and PV, are chronic blood diseases that can impact patients’ quality of life and lead to life-threatening complications, including the development of specific types of blood cancers, and PharmaEssentia is committed to developing new therapeutic solutions for these patients,” said Robert B. Geller, M.D., Head of Medical at PharmaEssentia USA. “We are thrilled with the pace at which we have enrolled patients, which we believe reflects a high level of interest in both the EXCEED-ET and ECLIPSE-PV trials. Our goal with each of these programs is to redefine the early treatment paradigm of myeloproliferative neoplasms.”

Sovato Announces Multiple Successful Remote Robotic-Assisted Procedures Over a 500-Mile Distance with the Use of the Sovato Platform

June 25, 2024

Sovato, a company enabling remote surgery and procedures, announced the use of the Sovato Platform in the successful completion of a series of remote robotic-assisted surgery (RAS) procedures in a preclinical technology demonstration. As part of the preclinical tests, seven surgeons across four specialties performed Nephrectomy, Hysterectomy, Colectomy, and Cholecystectomy procedures, validating the broad application of remote surgery.

The preclinical test results and surgeon experience were presented at the Society of Robotic Surgery 2024 Annual Meeting in Orlando, Florida. The surgeons completed a user experience assessment based on the NASA Task Load Index, a self-evaluation tool used to measure a subjective mental workload assessment of a participant while performing a task. The results revealed a high degree of confidence while performing the remote procedures. Surgeons also reported the ability to communicate effectively with the bedside assistant and having comparable situational awareness of the remote operating room compared to in-person surgery.

“I could not tell the difference between doing surgery in my operating room or in an operating room that was 500 miles away,” stated Francesco Bianco, MD, Associate Professor of Surgery, Division of General, Minimally Invasive & Robotic Surgery Department of Surgery, at the University of Illinois, Chicago, who presented the results. “The experience was seamless. There was no detectable delay. There was absolute comfort in communicating with the team on the remote side. Everything looked like a normal day in my operating room.”

The Sovato Platform is a first-of-its-kind, comprehensive solution for enabling and orchestrating remote robotic-assisted surgeries and procedures. Sovato brings together the remote surgery ecosystem, including healthcare providers and any RAS system, to deliver the curated fiberoptic network, clinical workflows, data, and supporting infrastructure required to enable safe, scalable, and profitable remote surgery and procedure programs. For healthcare organizations, Sovato’s platform supports the complete remote surgery program spanning the entire surgical journey for surgeons, care teams, and patients.

In the preclinical tests, the Sovato Platform was paired with a modified version of Virtual Incision’s MIRA Surgical System to enable surgeons from multiple disciplines to perform the procedures across a 500-mile distance. The Sovato Platform enabled low latency, curated, fiberoptic connectivity from the surgeon console to control MIRA’s arms and integrated an articulating camera at the remote location for full situational awareness. Surgeons maintained immersive verbal and visual communication with the remote care team using the Sovato Platform.

“Remote surgery offers the ability for surgeons and healthcare teams to care for patients who may not have access to minimally invasive surgery in many parts of the world,” stated Marty Martino, MD, Medical Director, Gynecologic Oncology and Robotic Surgery at Ascension St. Vincent’s. “To think about a surgeon located in one city and performing a remote surgery more than 500 miles away – all while feeling like you’re right there in person with the patient and care team – is history in the making.”

Remote surgery will help address the needs of more than half the world’s population that does not currently have access to high-quality surgical care, including 83 million Americans who must travel for routine procedures.1 Robotic-assisted technologies have the potential to enable minimally invasive surgery for these patients by allowing a surgeon to operate from a distant location. Miniaturized RAS systems, like MIRA, can further impact the process through simplified transportation and storage, making remote surgery a more feasible option for more hospitals.

“Sovato’s position is that the user experience is fundamental to drive adoption. Capturing the surgeon’s confidence in the technology and workflows is everything,” said Cynthia Perazzo, CEO and co-founder of Sovato. “These preclinical tests highlight that with the right tools and supporting infrastructure, remote surgery can mimic, and even improve, the experience for the surgeon and care teams. We are grateful to Virtual Incision’s partnership in making these preclinical tests a success. We share a vision of democratizing access to high-quality surgical care at a much larger scale, and these tests underscore we are on the right path to making this vision a reality.”

The preclinical tests were performed on porcine models between Lincoln, NE, and Chicago, IL, by the following surgeons:

Dr. Francesco Bianco, General Surgery – University of Illinois, Chicago
Dr. Michael Fabrizio, Urology – Urology of Virginia
Dr. Gerald Gantt, Colorectal Surgery – University of Illinois, Chicago
Dr. Gregory Heidrick, Obstetrics & Gynecology – Lincoln OB/GYN
Dr. Michael Jobst, General & Colorectal Surgery – Bryan Health
Dr. Martin Martino, Gynecologic Oncology – Ascension St. Vincent’s
Dr. James Porter, Urology – Providence St. Joseph Health

Introducing ScoliCare ® Denver Colorado | A New Hope for Individuals with Scoliosis

June 25, 2024

Individuals with scoliosis in Colorado now have access to a world-leading scoliosis treatment center with the opening of ScoliCare Denver Colorado. The clinic aims to transform the lives of patients with a non-surgical scoliosis specific approach, state-of-the-art facilities, and a highly experienced healthcare team.

Scoliosis affects up to 5% of young people and up to 68% of those over 60 and its prevalence is growing in the USA due to the aging population. The condition is characterized by an abnormal curvature of the spine.

ScoliCare clinics provide in-depth assessments and treatment plans for infants, children, adolescents, and adults. Treatment options include the world-leading ScoliBrace® bracing system and ScoliBalance®, a physiotherapeutic scoliosis-specific exercise program.

“Traditionally surgery was thought to be the only option for people with scoliosis however now, if we catch the curve early enough, we can prevent surgery,” explained Dr. Chris Gubbels D.C., Head Clinician at ScoliCare Denver Colorado. “We recognize the difficulties scoliosis can present, and our dedicated team is devoted to supporting patients throughout their treatment journey to achieve the best possible outcomes and enhance quality of life.”

Patient Success Story: Eric’s Journey

Dr. Gubbels has many years of experience treating scoliosis in collaboration with ScoliCare. One of his patients, Eric was first diagnosed at 11 years old and his curve continued to progress. While in college Eric injured his spine in a rock climbing accident which impacted his scoliosis and he was faced with physical discomfort and emotional distress. He began looking for treatment options as he was worried he would end up needing surgery. That’s when he found Dr. Gubbels who diagnosed Eric with severe scoliosis. With a customized ScoliBrace® and a tailored ScoliBalance® exercise program provided by ScoliCare, Eric’s curve significantly improved. Eric’s experience with Dr. Gubbels and his treatments have since inspired him to pursue a healthcare career.

American Academy of Nursing Announces the 2024 Class of New Fellows

June 25, 2024

The American Academy of Nursing (Academy) announces today that it will induct a distinguished cohort of nurse leaders as its 2024 Fellows. The inductees will be recognized for their substantial and sustained impact on health and health care at the Academy’s annual Health Policy Conference, taking place on October 31 – November 2, 2024 in Washington, DC. This year’s conference theme is “Courageous Transformations Towards an Equitable Future.”

The newest Fellows represent 37 states, the District of Columbia, Guam, and 14 countries. Their expansive body of knowledge will soon bolster the collective impact of over 3,000 Academy Fellows who together, leverage their expertise to advance the Academy’s vision of healthy lives for all people.

“I am thrilled to welcome these impressive nurse leaders into our organization. With exceptional subject matter expertise, each new Fellow will be vital to achieve the Academy’s mission of improving health and achieving health equity by impacting policy through nursing leadership, innovation, and science,” said Academy President Linda D. Scott, PhD, RN, NEA-BC, FNAP, FAAN. “Induction into the Academy represents the highest honor in nursing. Earning the FAAN (Fellow of the American Academy of Nursing) credential is a significant recognition of one’s accomplishments and signifies the future impact they will make in collaboration with their colleagues in the Academy.”

The 2024 Class of Fellows, selected from a competitive pool of applicants, represents a cross-section of nursing’s most dynamic leaders who are making positive change in their systems and communities to champion health and wellness. The Academy will host the Induction Ceremony and Soiree on the evening of Saturday, November 2, 2024. This event is a special tribute to showcase nursing leadership, science, and innovation where colleagues, family, friends, and sponsors can gather together in Washington, DC to celebrate the power of nursing to transform health. Learn more about the Academy and visit the policy conference website for more details.

2024 Academy Fellows*

Africa

South Africa

Portia J. Jordan, PhD, MBA, MCur, BCur, RN, RM, CCN – Stellenbosch University

Americas

Canada

Denise E. Bryant-Lukosius, PhD, MSc, BScN, RN, CON(C) – McMaster University School of Nursing

Kristin Cleverley, PhD, MSc, RN, CPMHN – University of Toronto Lawrence Bloomberg Faculty of Nursing

Samantha J. Mayo, PhD, RN – University of Toronto Lawrence Bloomberg Faculty of Nursing

Sheryl Reimer-Kirkham, PhD, RN – Trinity Western University School of Nursing

United States

Alabama

Kristi A. Acker, PhD, DNP, FNP-BC, AOCNP, ACHPN, FAANP – The University of Alabama Capstone College of Nursing

Wesley D. Davis, DNP, ENP-C, FNP-C, AGACNP-BC, FAANP, FAEN – University of South Alabama College of Nursing

Amy S.D. Lee, DNP, ARNP, WHNP-BC – The University of Alabama Capstone College of Nursing

Cordelia C. Nnedu, PhD, MSN, BSN, RN, CNM, WHNP-BC, CNE, ANEF – Tuskegee University School of Nursing

Courtney Sullivan, PhD, RN, CPNP-AC, CPHON – University of Alabama at Birmingham School of Nursing

Arkansas

Thomas A. Kippenbrock, EdD, RN – University of Arkansas Eleanor Mann School of Nursing

Jamie L. Wiggins, PhD, MBA, RN, CPN, NEA-BC, FACHE – Arkansas Children’s, Inc.

California

Angela D. Banks, PhD, RN – University of San Francisco School of Nursing and Health Professions

Thomas W. Barkley, PhD, ACNP-BC, ANP, FAANP – Barkley & Associates, Inc.

Marianne Biangone, PhD, RN, CNE, PHN – University of California San Francisco School of Nursing

Leslie Dubbin, PhD, MS, RN – University of California San Francisco School of Nursing

Leslie C. Evertson, DNP, RN, GNP-BC – UCLA Health

Vicki S. Good, DNP, RN, CENP, CPPS – American Association of Critical Care Nurses

Sharon B. Hampton, PhD, RN, NEA-BC – Kaiser Permanente, San Leandro

Lori S Kennedy, PhD, RN, ACNP-BC, CCRN-K, CNRN, FNCS – University of California Davis Health

Tracie W. Kirkland, PhD, DNP, ANP-BC, PPCPNP, CPNP-BC – University of Southern California

Annette S. Nasr, PhD, RN, MPA, NE-BC – Stanford Medicine Children’s Health

Michele M. Pelter, PhD, RN, FAHA – University of California San Francisco School of Nursing

Elizabeth A. Scruth, PhD, MPH, RN, CCNS, CCRN, FCCM, FCNS, CPHQ – Northern California Kaiser Permanente Hospitals and Health Plan

Stephanie A. Vaughn, PhD, RN, CRRN, FAHA, FARN – California State University, Fullerton

Colorado

Amanda D. Quintana, DNP, RN, FNP – Colorado Center for Nursing Excellence

Samantha B. Stonbraker, PhD, MPH, RN – University of Colorado College of Nursing

Christi Zuber, PhD, MHA, RN – Stanford Health Care & Aspen Labs

Connecticut

Nancy C. Banasiak, DNP, PPCNP-BC, APRN – Yale University School of Nursing

Mary Ann Camilleri, JD, BSN, RN, FACHE – Yale University School of Nursing

Eileen J. Carter, PhD, RN – University of Connecticut School of Nursing

Shelli L. Feder, PhD, APRN, FNP-C, ACHPN, FPCN, FAHA – Yale University School of Nursing

Mallory A. Perry-Eaddy, PhD, RN, CCRN – University of Connecticut School of Nursing

S. Raquel Ramos, PhD, MBA, MSN, FNP, FNYAM, FAHA – Yale University School of Nursing

Angela Richard-Eaglin, DNP, MSN, FNP-BC, FAANP, CDE – Yale University School of Nursing

Christine Rodriguez, DNP, APRN, FNP-BC, MDiv, MA, FNYAM – Yale University School of Nursing

Delaware

Michelle L. Collins, DNP, APRN, CNS, ACNS-BC, NPD-BC, NEA-BC, LSSBB – Christiana Care Health System

Danielle A. Sarik, PhD, APRN, CPNP-PC – Nicklaus Children’s Hospital

District of Columbia

Sandra Davis, PhD, DPM, ACNP-BC – National League for Nursing

Alison Hernandez, PhD, MS, RN – U.S. Senate Special Committee on Aging

Adrianna Nava, PhD, MPA, MSN, RN – National Committee for Quality Assurance

Florida

Laurie Abbott, PhD, RN, DipACLM, PHNA-BC – Florida State University College of Nursing

Francine Bono-Neri, PhD, RN, APRN, PNP – Nova Southeastern University College of Nursing

Staja Q. Booker, PhD, RN – University of Florida College of Nursing

Giovanna C. De Oliveira, PhD, MSN, RN, ANP-C, PMHNP-BC – University of Miami School of Nursing and Health Studies

Beth M. King, PhD, APRN, PMHNP-BC – Florida Atlantic University Christine E. Lynn College of Nursing

Yui Matsuda, PhD, PHNA-BC, MPH – University of Miami School of Nursing and Health Studies

Angela S. Prestia, PhD, MSN, RN, NE-BC – Florida Atlantic University & Case Western Reserve University

Linda F. Robinson, MSN, RN, CPXP – MDM Commercial Healthcare

Natasha Schaefer Solle, PhD, MSN, RN – University of Miami, Sylvester Comprehensive Cancer Center

Jorge A. Valdes, DNP, CRNA, APRN, FAANA – Florida International University Nicole Wertheim College of Nursing & Health Sciences

Lisa A. Wiese, PhD, MSN, RN, GERO-BC, PHNA-BC, CNE, FGSA – Florida Atlantic University Christine E. Lynn College of Nursing

Georgia

Glenna S. Brewster, PhD, RN, FNP-BC – Emory University Nell Hodgson Woodruff School of Nursing

C. Renee Byfield, MS, RN, FNP, C-EFM – Institute for Perinatal Quality Improvement

Ethan Cicero, PhD, RN – Emory University Nell Hodgson Woodruff School of Nursing

Pamela R. Cromer, DNP, FNP-BC, FAANP – Augusta University College of Nursing

Carrie M. McDermott, PhD, RN, APRN, ACNS-BC – Emory Healthcare

Chinomso U. Nwozichi, PhD, RN, CMSRN – Kennesaw State University Wellstar School of Nursing

Quyen T. Phan, DNP, APRN, FNP-BC – Emory University Nell Hodgson Woodruff School of Nursing

Courtney J. Pitts, DNP, MPH, FNP-BC, FAANP – Emory University Nell Hodgson Woodruff School of Nursing

Mary Dioise Ramos, PhD, RN, CNE – Kennesaw State University Wellstar School of Nursing

David A. Reinhart, DNP, MBA, RN, CNOR – Emory Healthcare

Irene Yang, PhD, RN – Emory University Nell Hodgson Woodruff School of Nursing

Guam

The Honorable Lourdes Leon Guerrero, MPH, BSN, RN – Government of Guam

Hawaii

Jill Hoggard Green, PhD, RN – The Queen’s Health System

Illinois

Aney Abraham, DNP, RN, NE-BC – Rush University Medical Center College of Nursing

Elizabeth A. Aquino, PhD, RN – University of Illinois at Chicago College of Nursing

Anne Deutsch, PhD, RN – Shirley Ryan AbilityLab

Beverly J. Hancock, DNP, RN, NPD-BC, CENP – American Organization for Nursing Leadership

Dave Hanson, MSN, RN, ACNS-BC, NEA-BC – Society of Critical Care Medicine (In Memoriam)

Cynthia M. LaFond, PhD, RN, CCRN-K – Ascension

Hongjin Li, PhD, RN, BSN – University of Illinois at Chicago College of Nursing

Jenny O’Rourke, PhD, APRN, CHSE – Loyola University Chicago School of Nursing

Beena S. Peters, DNP, MS, RN, FACHE, FABC – Cook County Hospital and Health System

Jill M. Price, PhD, RN, MSN – Chamberlain University

Monique M. Ridosh, PhD, RN – Loyola University Chicago School of Nursing

Tanya R. Sorrell, PhD, PMHNP-BC – Rush University Medical Center College of Nursing

Indiana

Elizabeth A. Richards, PhD, RN, CHES – Purdue University School of Nursing West Lafayette, Main Campus

Vicki L. Simpson, PhD, RN, CHES – Purdue University School of Nursing West Lafayette, Main Campus

Jane R. von Gaudecker, PhD, RN, AGCNS, FAES, CGNC – Indiana University School of Nursing

Iowa

Wen Liu, PhD, RN, FGSA – University of Iowa College of Nursing

Juliana N. Souza-Talarico, PhD, MSN, BSN, RN – University of Iowa College of Nursing

Kansas

Cara A. Busenhart, PhD, APRN, CNM, FACNM – University of Kansas School of Nursing

Kentucky

Luz G. Huntington-Moskos, PhD, RN, CPN – University of Louisville School of Nursing

Louisiana

Tavell L. Kindall, PhD, DNP, APRN, FNP-BC – St. Thomas Community Health Center

Maine

Cheryl Nimmo, DNP, MSHSA, CRNA, FAANA – University of New England

Maryland

Christine E. Bader, PhD, RN, NEA-BC – Uniformed Services University of the Health Sciences

Sabrina Beroz, DNP, RN, CHSE-A, ANEF – Montgomery College School of Nursing

Jennifer A. Graebe, MSN, RN, NEA-BC – American Nurses Credentialing Center

Melissa D. Hladek, PhD, CRNP, FNP-BC – Johns Hopkins University School of Nursing

Danielle K. McCamey, DNP, ACNP-BC, FCCP – Johns Hopkins University School of Nursing

Kim Mooney-Doyle, PhD, RN, CPNP-AC – University of Maryland School of Nursing

Gregory Raymond, DNP, MBA, RN, NEA-BC – University of Maryland Medical Center

Cynthia M. Rubio, PhD, MHS, BSN, NHDP-BC – United States Public Health Service, US Department of Health and Human Services

Laurie A. Saletnik, DNP, RN, CNOR – The Johns Hopkins Hospital

Franz A. Vergara, DNP, PhD, MAS, RN, CENP, CCM, ONC – MedStar Health

Massachusetts

Suha Ballout, PhD, RN – University of Massachusetts Boston

Jeungok Choi, PhD, RN, MPH – University of Massachusetts Amherst Elaine Marieb College of Nursing

Jessica S. Dillard-Wright, PhD, MA, RN, CNM – University of Massachusetts Amherst Elaine Marieb College of Nursing

Priscilla K. Gazarian, PhD, CNS, RN – University of Massachusetts Boston

Clara M. Gona, PhD, FNP-BC – MGH Institute of Health Professions School of Nursing

Cherlie Magny-Normilus, PhD, FNP-BC, FNYAM – Boston College Connell School of Nursing

Joan M. Meunier-Sham, MS, RN – Massachusetts Department of Public Health

Jinhee Park, PhD, RN – Boston College Connell School of Nursing

Memnun Seven, PhD, MS, RN – University of Massachusetts Amherst Elaine Marieb College of Nursing

Brittney J. van de Water, PhD, RN, CPNP-PC – Boston College Connell School of Nursing

Michigan

Meriam Caboral-Stevens, PhD, RN, NP – Eastern Michigan University

Toni L. Glover, PhD, GNP-BC, ACHPN – Oakland University School of Nursing

Dawn M. Goldstein, PhD, RN, PMHNP-BC – Michigan State University College of Nursing

Kathleen A. Poindexter, PhD, MSN, RN, CNE, ANEF – Michigan State University College of Nursing

Kathleen A. Schachman, PhD, FNP-BC, PMHNP-BC, FIAAN, FAANP – Saginaw Valley State University

Minnesota

Robin R. Austin, PhD, DNP, DC, NI-BC, FAMIA, FNAP – University of Minnesota School of Nursing

Rhonda Kazik, DNP, RN, CENP – Essentia Health Integrated Healthcare System

Heidi L. Lindroth, PhD, RN – Mayo Clinic

Mississippi

Kayla L. Carr, PhD, RN, FNP-C – Mississippi State University

Missouri

Elizabeth A. Monsees, PhD, MBA, RN, CIC, FAPIC, FSHEA – Children’s Mercy Hospital

Nebraska

Martha J. Todd, PhD, APRN-NP – Creighton University College of Nursing

Nevada

Alexa C. Curtis, PhD, MPH, APRN, FAANP – University of Nevada, Reno Orvis School of Nursing

Reimund Serafica, PhD, APRN, PMHNP-BC, FTNSS,CNE – University of Nevada, Las Vegas School of Nursing

New Jersey

Emilia N. Iwu, PhD, RN, APNC – Rutgers School of Nursing

New York

Veronica Barcelona, PhD, MSN, RN, PHNA-BC – Columbia University School of Nursing

Melissa P. Beauchemin, PhD, MSN, BSN, BA, CPNP-PC, CPON – Columbia University School of Nursing

Dewi V. Brown-DeVeaux, DNP, BS, RN-ONC – NYU Langone Health

Jane K. Dickinson, PhD, RN, CDCES – Teachers College Columbia University

Ashley R. Graham-Perel, EdD, RN, NPD-BC, MEDSURG-BC, CNE – Columbia University School of Nursing

Heidi Hahn-Schroeder, DNP, RN – Columbia University School of Nursing

Tara N. Heagele, PhD, RN – The City University of New York Hunter-Bellevue School of Nursing

Margaret M. McCarthy, PhD, RN, FNP-BC – New York University Rory Meyers College of Nursing

Rebecca A. Owens, DNP, MBA, MSN, RN, PMH-BC – New York State Psychiatric Institute and Columbia University School of Nursing

Darcel M. Reyes, PhD, ANP-BC – City University of New York Lehman College School of Health Sciences, Human Services & Nursing

Lydia D. Rotondo, DNP, RN, CNS, FNAP – University of Rochester School of Nursing

Tina R. Sadarangani, PhD, RN, ANP-BC, GNP-BC – New York University Rory Meyers College of Nursing

Marsha C. Sinanan, MSN, MBA, RN NEA-BC, CPXP – Mount Sinai Health System

Andrea Sonenberg, PhD, WHNP, CNM-BC, FNYAM, FNAP – Pace University Lienhard School of Nursing

Edwidge J. Thomas, DNP, ANP-BC – Northwell Health

Jasmine Travers, PhD, MHS, RN, AGPCNP-BC – New York University Rory Meyers College of Nursing

Fabienne G. Ulysse, DNP, AOCNP, MSN, ANP – Maimonides Medical Center

Kenya D. Williams, EdD, MBA, MSN, RN, RP, CAE, FNYAM – National Student Nurses’ Association

Linda Zieman, DNP, MM, MSN, RN, CEN, NEA-BC – Hospital for Special Surgery

North Carolina

April A. Braswell, PhD, APRN, CPNP-PC, CNE – University of North Carolina Wilmington School of Nursing

Nancy Crego, PhD, RN, CHSE – Duke University School of Nursing

Jean A. Davison, DNP, RN, FNP-BC – University of North Carolina at Chapel Hill School of Nursing

Robert T. Dodge, PhD, RN, ANP, AACRN, FAANP – University of North Carolina School of Medicine

Rhonda R. Foster-Smith, EdD, MPH, MS, RN, ACC – David Couper Consulting
Kellie M. Griggs, DNP, MSN, RNC-OB – University of North Carolina Wilmington School of Nursing

Michael L. Jones, PhD, MBA/HCM, RN – East Carolina University College of Nursing

Allison A. Lewinski, PhD, MPH, RN – Duke University School of Nursing & Durham Veterans Affairs Health Care System

Devon Noonan, PhD, MPH, FNP-BC, CARN – Duke University School of Nursing

Hanzhang Xu, PhD, RN – Duke University School of Nursing

Ohio

Mary K. Anthony, PhD, RN – Kent State University and University Hospitals of Cleveland

Patricia G. Bondurant, DNP, RN – TransForm Healthcare Consulting, LLC

Evelyn G. Duffy, DNP, AGPCNP-BC, FAANP – Case Western Reserve University Frances Payne Bolton School of Nursing

Christine A. Fortney, PhD, RN, FPCN – The Ohio State University College of Nursing

Shannon L. Gillespie, PhD, RN – The Ohio State University College of Nursing

Jacqueline Hoying, PhD, RN, NBC-HWC, FNAP – The Ohio State University College of Nursing

Airica D. Steed, EdD, MBA, RN, CSSMBB, FACHE, IASSC – MetroHealth System

Oklahoma

Judy Goforth Parker, PhD, APRN, CNP, FACHE – The Chickasaw Nation

Julie A. Hoff, PhD, MPH, RN, CENP – University of Oklahoma Fran and Earl Ziegler College of Nursing

Shelly Wells, PhD, MBA, MS, APRN-CNS, BC-CNS, ANEF – Northwestern Oklahoma State University

Oregon

Laura M. Criddle, PhD, ACNS-BC, CCNS, CCRN, CEN, CPEN, CFRN, CTRN, TCRN, CBRN, NRP FP-C, CCP-C, FAEN – TCAR Education Programs

Pennsylvania

Rebecca R.S. Clark, PhD, MSN, RN, CNM, WHNP-BC – University of Pennsylvania School of Nursing/Pennsylvania Hospital

Jill Demirci, PhD, RN, IBCLC – University of Pittsburgh School of Nursing

Louise D. Jakubik, PhD, RN, NPD-BC, CSP – Nurse Builders

Anna E. Schoenbaum, DNP, MS, RN, NI-BC, FHIMSS – Penn Medicine (University of Pennsylvania Health System)

Daniel J. Smith, PhD, AGPCNP-BC, CNE – Villanova University M. Louise Fitzpatrick College of Nursing

South Carolina

Lorie Donelle, PhD, RN, FCAN – University of South Carolina College of Nursing

Terri O. Fowler, DNP, APRN, NP-C – Medical University of South Carolina College of Nursing

Kelli Garber, DNP, APRN, PPCNP-BC – Old Dominion University School of Nursing

Karen Kane McDonnell, PhD, RN – University of South Carolina College of Nursing

Angela Mund, DNP, CRNA – Medical University of South Carolina College of Health Professions

Mary Ellen Wright, PhD, APRN, CPNP-PC – Clemson University School of Nursing

Tennessee

Bobby Bellflower, DNSc, NNP-BC – University of Tennessee Health Science Center College of Nursing

Beth F. Hallmark, PhD, MSN, RN, CHSE-A, ANEF – Belmont University Gordon E. Inman College of Nursing

Keesha L. Powell-Roach, PhD, RN – University of Tennessee Health Science Center College of Nursing

Deonni P. Stolldorf, PhD, RN – Vanderbilt University School of Nursing

Texas

Ninotchka Brydges, PhD, DNP, MBA, APRN, ACNP-BC, FNAP – University of Texas Medical Branch Department of Internal Medicine

Heather E. Cuevas, PhD, APRN, ACNS-BC – The University of Texas at Austin School of Nursing

Christi T. Nguyen, DNP, RN, FACHE, NEA-BC – UT Southwestern Medical Center

Angela Ross, DNP, RN, MPH, PMP, DASM, PHCNS-BC, FHIMSS – University of Texas Health Science Center Houston McWilliams School of Biomedical Informatics

Cheryl A. Thaxton, DNP, APRN, CPNP, FNP-BC, CHPPN, FPCN, FAANP – University of North Texas Health Science Center College of Nursing

Utah

Nancy A. Allen, PhD, ANP-BC, FADCES – University of Utah College of Nursing

Linda C. Hofmann, PhD, RN, NEA-BC, NE-BC – University of Utah College of Nursing

Shelly J. Reed, PhD, DNP, MSN, APRN, CNM – Brigham Young University College of Nursing

Virginia

Kathy M. Baker, PhD, RN, NE-BC – University of Virginia Medical Center

Joan (Joni) M. Brady, DNP, RN, PMGT-BC, CAPA – Inova Health System

Lisa F. Brown, PhD, RN – Virginia Commonwealth University School of Nursing

Cathy L. Campbell, PhD, RN – University of Virginia School of Nursing

Helen Caton-Peters, MSN, RN, HCISPP – World Health Organization

Gwendolyn A. Foster, DrPH(c), CNM, FAANP, FACNM – United States Air Force

Tina S. Gustin, DNP, CNS, RN – Old Dominion University School of Nursing

Jerrol B. Wallace, DNP, CRNA, FAANA – United States Navy

Washington

Patsy L. Maloney, EdD, RN, MSN, NPD-BC, NEA-BC, CEN – University of Washington Tacoma School of Nursing & Healthcare Leadership

Jillian Pintye, PhD, MPH, BSN, RN – University of Washington School of Nursing

Asia

China

Aihua Chen, BSN, RN – Panhealth International Hospital

Beirong Mo, PhD(c), MBA, BN, RN – Shenzhen Sixth People’s Hospital (Nanshan Hospital) Huazhong University of Science and Technology Union Shenzhen Hospital

Changying Chen, PhD, RN – The First Affiliated Hospital of Zhengzhou University, Institute for Hospital Management Research of Henan Province

Renli Deng, DNS, MSc, BN, RN – Zunyi Medical University (ZMU)/ Affiliated Hospital of ZMU

PingPing He, PhD, RN – Hunan Normal University

Binchun Hu, BSN, RN – Zhejiang Medical Service Management Evaluation Center

Juan Li, PhD – Fudan University Huashan Hospital

Lingli Li, DN – West China Hospital, Sichuan University

Wentao Li, PhD, MPH, BSN – Dalian University School of Nursing

Biru Luo, PhD, MSc, BSc, RN – West China Second University Hospital

Tieying Shi, MM, BN, RN – The First Affiliated Hospital of Dalian Medical University

Chao Sun, PhD(c), MS, BSN, RN – Beijing Hospital

Dongmei Wu, PhD, RN – The Fourth People’s Hospital of Chengdu & The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China

Li Zhang, MM, RN – The First People’s Hospital of Foshan

Hong Kong

Ka Ming Chow, DN, RN, RM, FHKAN, APN – The Chinese University of Hong Kong The Nethersole School of Nursing

Rick Kwan, PhD, RN, FHKAN – Tung Wah College School of Nursing

Jojo Yan Yan Kwok, PhD, MPH, BN, RN, MHKAN – The University of Hong Kong School of Nursing

India

Suresh Sharma, PhD, RN, MSN, FNRS – All India Institute of Medical Sciences College of Nursing

Singapore

Shefaly Shorey, PhD, RN , RM – National University of Singapore

South Korea

Chiyoung Cha, PhD, RN – Ewha Womans University

Taiwan

Cheryl Chia-Hui Chen, DNSc, MSN, BSN, RNC – National Taiwan University School of Nursing

Hui-Hsun Chiang, PhD, RN – National Defense Medical Center

Ya-Chu Hsiao, EdD, RN – Chang Gung University of Science and Technology

Shu-Yu Kuo, PhD, RN – Taipei Medical University

Europe

Ireland

Georgina T. Gethin, PhD, MSc, RGN – University of Galway School of Nursing & Midwifery

Catrina Heffernan, DN, MSc, BSc, PGDE, RN, SFHE – Munster Technological University

Natalie L. McEvoy, PhD, RN – Royal College of Surgeons in Ireland

Italy

Rosario Caruso, PhD, MSN, RN – University of Milan & IRCCS Policlinico San Donato

Switzerland

Manuela R.E. Eicher, PhD, MScN, BScN – University of Lausanne and Lausanne University Hospital

Franziska Zúñiga, PhD, RN – University of Basel

Turkey

Ayise Karadag, PhD, MSN, RN, ET-WOCN – Koç University School of Nursing

United Kingdom

Uduak E. Archibong, PhD, RN, FRCN, FWACN – University of Bradford

Jonathan E. Asbridge, DS(h), DHS(h), RN – Sciensus Pharma Services Ltd

Gina M.A. Higginbottom, PhD, RN, RM, RHV – NHS Race and Health Observatory

John Unsworth, PhD, LLM, MSc, BSc, BA, RN, PGCE, NTF, PFHEA, FEANS, FFNMRSCI, OBE – Northumbria University

Emma L. Wadey, PhD, MSc, PG Cert, PG Dip, BSc, RNMH – NHS England

Oceania

Australia

Kate Curtis, PhD, RN – University of Sydney

Jane L. Phillips, PhD, RN, FACN, FPCNA – Queensland University of Technology

*This list notes the information provided by the incoming Fellows as of June 24, 2024. Please note, these individuals will officially become an Academy Fellow and may use the FAAN credential only after they participate in the Induction Ceremony on November 2, 2024 in Washington, DC.

What is the PillCam?

Pros of the PillCam

Cons of the PillCam

Conclusion

Medical Device News Magazine